Volume 3, Issue 4, Pages 513-523 (November 2017) The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design  Daniela Bertens, Betty M. Tijms, Lisa Vermunt, Niels D. Prins, Philip Scheltens, Pieter Jelle Visser  Alzheimer's & Dementia: Translational Research & Clinical Interventions  Volume 3, Issue 4, Pages 513-523 (November 2017) DOI: 10.1016/j.trci.2017.08.005 Copyright © 2017 Terms and Conditions

Fig. 1 Schematic overview of the groups according to subclassification, applying the research criteria. Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; MCI, mild cognitive impairment; AD, Alzheimer's disease. Subject classification based on AD biomarkers: Preclinical AD, n = 146; 49 based on CSF measures only, 80 based on PET, and 17 subjects with both modalities present. Preclinical AD stage-1, n = 110; 33 based on CSF measures only, 60 based on PET, and 17 with both modalities present. Preclinical AD stage-2, n = 34; 16 based on CSF measures only, 17 based on PET, and 1 with both modalities present. For two cognitively normal subjects, we did not have any information of their injury status so they could not be further classified into stage-1 or stage-2. Prodromal AD, n = 420; 149 based on CSF measures only, 148 based on PET, and 123 with both modalities present. Prodromal AD stage-1, n = 216; 63 based on CSF measures only, 88 based on PET, and 65 with both modalities present. Prodromal AD stage-2, n = 197; 85 based on CSF measures, 59 based on PET, 53 with both modalities present. For seven MCI subjects, we did not have any information of their injury status, so they could not be further classified into stage-1 or stage-2. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 513-523DOI: (10.1016/j.trci.2017.08.005) Copyright © 2017 Terms and Conditions